Finance entity

Integra LifeSciences

Company IART

Every one of those 1 sits in a single category, earnings. Acclarent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window.

Last mentioned: Feb 26, 2026

Entity pulse

Recent coverage · Integra LifeSciences

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Integra LifeSciences

Every one of those 1 sits in a single category, earnings. Acclarent is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 6 in the same window. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Finance story that mention Integra LifeSciences, all published on February 26, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Integra LifeSciences. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Earnings

    Company reports results and provides 2026 guidance, signaling continued remediation efforts.

  2. Projected Restart

    Target window for the commercial re-launch of SurgiMend and PriMatrix products.

  3. New Leadership

    Mojdeh Poul assumes role as CEO to lead the company's quality and operational turnaround.

  4. Boston Recall

    Integra initiates voluntary recall of all products manufactured in Boston due to endotoxin concerns.

Stories mentioning Integra LifeSciences 1

Earnings Neutral

Integra LifeSciences Faces Market Pressure as Turnaround Timeline Extends

Integra LifeSciences (IART) shares faced downward pressure following its Q4 2025 earnings call, as management detailed an extended timeline for its Boston facility restart and the ongoing costs of its Quality Excellence Program. While the company provided its first full-year 2026 guidance, investor caution remains high regarding the path to normalized growth and product re-launches.

2 sources

Integra LifeSciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.